Ranked #1,876 of 8,699 institutional investors
Logos Global Management LP
San Francisco, CA
$1.45B
US stock portfolio at live prices · today +$2.2M (+0.15%)
Market closed. Prices as of Nov 20, 7:41 AM ET
- Value at quarter end (Q3 2026)
- $1.65B
- Change from Q2 2026
- −$668.2M (−28.77%)
- Positions
- 49 · 12 new, 22 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: call options on $202M of stock. $60.4M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesPRAX 9.09%RVMD 6.58%ERAS 5.77%CGON 5.49%IRON 5.32%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| PRAX Praxis Precision Medicines, Inc. | 425,000 | $132M | 9.09% | Added +63% |
| RVMD Revolution Medicines, Inc. | 600,000 | $95.7M | 6.58% | Reduced −14% |
| ERAS Erasca, Inc. | 5,900,000 | $83.9M | 5.77% | Reduced −51% |
| CGON CG Oncology, Inc. | 975,000 | $79.9M | 5.49% | Reduced −3% |
| IRON Disc Medicine, Inc. | 1,015,000 | $77.3M | 5.32% | Added +16% |
| IDYA IDEAYA Biosciences, Inc. | 2,850,000 | $74.6M | 5.13% | Reduced −5% |
| ABVX ABIVAX Société Anonyme | 870,000 | $70.2M | 4.83% | Reduced −15% |
| BNTX BioNTech SE | 650,000 | $52.9M | 3.64% | Reduced −36% |
| ELVN Enliven Therapeutics, Inc. | 1,080,000 | $50.1M | 3.45% | Added +132% |
| TNGX Tango Therapeutics, Inc. | 2,150,000 | $48.8M | 3.36% | Reduced −25% |
| DYN Dyne Therapeutics, Inc. | 3,000,000 | $48.1M | 3.31% | Added +18% |
| DNTH Dianthus Therapeutics, Inc. | 500,000 | $42.4M | 2.92% | Reduced −38% |
| MDGL Madrigal Pharmaceuticals, Inc. | 100,000 | $39.7M | 2.73% | New |
| NBIX Neurocrine Biosciences, Inc. | 250,000 | $39.1M | 2.69% | New |
| OCUL Ocular Therapeutix, Inc. | 6,000,000 | $35.2M | 2.42% | Added +13% |
| COGT Cogent Biosciences, Inc. | 1,250,000 | $34.7M | 2.39% | Added +39% |
| MAZE Maze Therapeutics, Inc. | 935,000 | $30.3M | 2.09% | Reduced −52% |
| BLTE Belite Bio, Inc | 200,000 | $30.2M | 2.08% | Reduced −20% |
| AXSM Axsome Therapeutics, Inc. | 175,000 | $23.7M | 1.63% | New |
| OLMA Olema Oncology, Inc. | 3,208,875 | $22.9M | 1.58% | Unchanged |
| MANE Veradermics Inc | 170,000 | $21.1M | 1.46% | Reduced −6% |
| PBLS Parabilis Medicines, Inc. | 750,000 | $20.7M | 1.43% | Added +43% |
| TRVI Trevi Therapeutics, Inc. | 1,445,000 | $19.8M | 1.36% | Reduced −23% |
| APMD Apnimed, Inc. | 1,100,000 | $19.0M | 1.31% | New |
| QUIT Achieve Life Sciences, Inc. | 3,200,000 | $18.8M | 1.29% | Reduced −41% |
| GPCR Structure Therapeutics Inc. | 1,000,000 | $17.1M | 1.18% | Added +100% |
| MLTX MoonLake Immunotherapeutics | 1,500,000 | $16.5M | 1.14% | Reduced −44% |
| VERA Vera Therapeutics, Inc. | 600,000 | $16.1M | 1.10% | Reduced −73% |
| AVBP ArriVent BioPharma, Inc. | 1,350,000 | $15.2M | 1.05% | Added +35% |
| YARW Yarrow Bioscience, Inc. | 1,026,258 | $14.6M | 1.00% | New |
| SRPT Sarepta Therapeutics, Inc. | 1,000,000 | $14.2M | 0.98% | New |
| IMCR Immunocore Holdings plc | 500,000 | $13.3M | 0.92% | Reduced −17% |
| DFTX Definium Therapeutics, Inc. | 350,000 | $10.3M | 0.71% | Added +338% |
| LBRX LB Pharmaceuticals Inc | 250,000 | $10.0M | 0.69% | Reduced −57% |
| DSGN Design Therapeutics, Inc. | 1,000,000 | $9.3M | 0.64% | Reduced −67% |
| ETRA Electra Therapeutics, Inc. | 1,000,000 | $8.9M | 0.62% | New |
| NERV Minerva Neurosciences, Inc. | 3,288,777 | $7.0M | 0.48% | Unchanged |
| VKTX Viking Therapeutics, Inc. | 200,000 | $5.2M | 0.36% | New |
| IRD Opus Genetics, Inc. | 1,000,000 | $4.1M | 0.28% | New |
| EDIT Editas Medicine, Inc. | 2,222,000 | $3.8M | 0.26% | Unchanged |
| JBIO Jade Biosciences, Inc. | 200,000 | $3.0M | 0.21% | Reduced −82% |
| IMVT Immunovant, Inc. | 85,000 | $2.8M | 0.19% | Reduced −87% |
| OKUR OnKure Therapeutics, Inc. | 963,855 | $2.7M | 0.18% | Unchanged |
| VOGX Vogenx, Inc. | 205,000 | $2.6M | 0.18% | New |
| UNCY Unicycive Therapeutics, Inc. | 473,563 | $1.7M | 0.12% | Unchanged |
| TNXP Tonix Pharmaceuticals Holding Corp. | 550,000 | $1.4M | <0.1% | New |
| SEPN Septerna, Inc. | 23,548 | $923K | <0.1% | Unchanged |
| PTN Palatin Technologies, Inc. | 129,260 | $637K | <0.1% | Reduced −1% |
| LGVN Longeveron Inc. | 192,308 | $350K | <0.1% | New |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| CLDX Celldex Therapeutics, Inc. | 2,100,000 | $58.7M |
| REPL Replimune Group, Inc. | 2,500,000 | $48.1M |
| CMPS COMPASS Pathways plc | 2,250,000 | $19.5M |
| XENE Xenon Pharmaceuticals Inc. | 450,000 | $16.9M |
| MLYS Mineralys Therapeutics, Inc. | 1,050,000 | $14.9M |
| RYTM Rhythm Pharmaceuticals, Inc. | 125,000 | $14.6M |
| SMMT Summit Therapeutics Inc. | 1,350,000 | $14.3M |
| VOR Vor Biopharma Inc. | 650,000 | $12.0M |
| RCUS Arcus Biosciences, Inc. | 650,000 | $10.3M |
| SRRK Scholar Rock Holding Corporation | 200,000 | $10.1M |
| ODTX Odyssey Therapeutics, Inc. | 521,736 | $9.6M |
| AMLX Amylyx Pharmaceuticals, Inc. | 350,000 | $9.2M |
| DBVT DBV Technologies S.A. | 915,000 | $8.6M |
| AVTX Avalo Therapeutics, Inc. | 1,150,000 | $7.8M |
| IMMX Immix Biopharma, Inc. | 1,000,000 | $7.0M |
| QTTB Q32 Bio Inc. | 800,000 | $6.8M |
| FTH Faeth Therapeutics, Inc. | 722,020 | $6.3M |
| RLAY Relay Therapeutics, Inc. | 350,000 | $5.6M |
| ANNX Annexon, Inc. | 1,500,000 | $5.1M |
| ACAD Acadia Pharmaceuticals Inc. | 250,000 | $4.4M |
| ACRS Aclaris Therapeutics, Inc. | 200,000 | $700K |
| TENX Tenax Therapeutics, Inc. | 300,000 | $417K |